MCID: JVN010
MIFTS: 69

Juvenile Rheumatoid Arthritis

Categories: Rare diseases, Bone diseases, Genetic diseases, Respiratory diseases

Aliases & Classifications for Juvenile Rheumatoid Arthritis

MalaCards integrated aliases for Juvenile Rheumatoid Arthritis:

Name: Juvenile Rheumatoid Arthritis 12 76 53 25 6 15 73
Juvenile Idiopathic Arthritis 12 53 25 37
Juvenile Arthritis 53 43 73
Monarticular Juvenile Rheumatoid Arthritis 12 73
Systemic Juvenile Rheumatoid Arthritis 12 25
Juvenile Chronic Polyarthritis 12 73
Arthritis, Juvenile Rheumatoid 53 25
Juvenile Chronic Arthritis 53 25
Acute Polyarticular Juvenile Rheumatoid Arthritis 73
Pauciarticular Onset Juvenile Chronic Arthritis 12
Pauciarticular Juvenile Rheumatoid Arthritis 73
Rheumatoid Arthritis, Systemic Juvenile 73
Acute Juvenile Rheumatoid Arthritis 12
Pauciarticular Juvenile Arthritis 12
Arthritis Juvenile Rheumatoid 55
Arthritis, Juvenile 44
Juvenile Ra 25
Jia 25
Jra 25

Classifications:



Summaries for Juvenile Rheumatoid Arthritis

MedlinePlus : 43 Juvenile arthritis (JA) is arthritis that happens in children. It causes joint swelling, pain, stiffness, and loss of motion. It can affect any joint, but is more common in the knees, hands, and feet. In some cases it can affect internal organs as well. The most common type of JA that children get is juvenile idiopathic arthritis. There are several other forms of arthritis affecting children. One early sign of JA may be limping in the morning. Symptoms can come and go. Some children have just one or two flare-ups. Others have symptoms that never go away. JA can cause growth problems and eye inflammation in some children. No one knows exactly what causes JA. Most types are autoimmune disorders. This means that your immune system, which normally helps your body fight infection, attacks your body's own tissues. JA can be hard to diagnose. Your health care provider may do a physical exam, lab tests, and x-rays. A team of providers usually treats JA. Medicines and physical therapy can help maintain movement and reduce swelling and pain. They may also help prevent and treat complications. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Juvenile Rheumatoid Arthritis, also known as juvenile idiopathic arthritis, is related to rheumatoid arthritis, systemic juvenile and rheumatoid factor-negative juvenile idiopathic arthritis, and has symptoms including back pain, muscle cramp and sciatica. An important gene associated with Juvenile Rheumatoid Arthritis is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and Jak-STAT signaling pathway. The drugs Infliximab and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include joint, testes and bone, and related phenotypes are uveitis and skin rash

Disease Ontology : 12 A rheumatoid arthritis that involves an autoimmune disease onset in children under 16 which attacks the healthy cells and tissue of located in joint.

Genetics Home Reference : 25 Juvenile idiopathic arthritis refers to a group of conditions involving joint inflammation (arthritis) that first appears before the age of 16. This condition is an autoimmune disorder, which means that the immune system malfunctions and attacks the body's organs and tissues, in this case the joints.

NIH Rare Diseases : 53 Juvenile idiopathic arthritis is an autoimmune condition that causes pain and swelling in a child's joints. When the immune system attacks the tissues of the joints, the resulting inflammation can cause joint damage, resulting in the pain and swelling characteristic of the disease. Some children who have juvenile idiopathic arthritis are affected by episodes where the symptoms worsen, called flares. Like most other autoimmune conditions, juvenile idiopathic arthritis is caused by a combination of genetic and environmental factors. To be diagnosed with juvenile idiopathic arthritis, the symptoms must have begun before age 16. Diagnosis of the condition may be based on blood tests, X-rays, and ruling out other similar conditions. Treatment options may include medications and  physical therapy.

Wikipedia : 76 Juvenile idiopathic arthritis (JIA), also known as juvenile rheumatoid arthritis, is the most common... more...

Related Diseases for Juvenile Rheumatoid Arthritis

Diseases in the Rheumatoid Arthritis family:

Rheumatoid Arthritis, Systemic Juvenile Juvenile Rheumatoid Arthritis

Diseases related to Juvenile Rheumatoid Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 353)
# Related Disease Score Top Affiliating Genes
1 rheumatoid arthritis, systemic juvenile 33.5 HLA-DRB1 IL1R1 IL6
2 rheumatoid factor-negative juvenile idiopathic arthritis 32.1 HLA-DRB1 IL2RA SLC11A1
3 systemic onset juvenile idiopathic arthritis 31.5 IL18 IL1B TNF
4 uveitis 31.2 IL1R1 IL2RA TNF
5 spondylarthropathy 31.0 LTA TNF
6 reactive arthritis 30.7 CRP IL6 TNF
7 kawasaki disease 30.6 CRP IL6 TNF
8 vasculitis 30.5 CRP S100A9 TNF TNFRSF1B
9 rubella 30.5 HLA-DPB1 HLA-DRB1 TNF
10 keratoconjunctivitis sicca 30.2 IL1B IL6 TNF
11 gingivitis 30.2 IL1B IL6 TNF
12 chronic fatigue syndrome 30.1 IL1B IL6 TNF
13 oligoarticular juvenile idiopathic arthritis 30.1 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL2RA TNF
14 pneumonia 30.1 CRP IL1B IL6 TNF
15 pericarditis 29.9 CRP IL1B IL6 TNF
16 meningitis 29.9 CRP IL1B IL6 TNF
17 cerebral palsy 29.9 IL1B IL6 LTA TNF
18 aseptic meningitis 29.5 IL1B IL1R1 IL1RN TNF
19 connective tissue disease 29.4 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL6 TNF
20 adult-onset still's disease 29.3 CRP IL18 IL1B IL1R1 IL1RN IL6
21 joint disorders 29.1 IL1B IL1R1 IL1RN IL6 TNF
22 psoriatic arthritis 28.9 CRP HLA-DRB1 IL1B IL6 LTA TNF
23 arthritis 28.8 HLA-DRB1 IL18 IL1B IL1RN IL6 LTA
24 osteoporosis 28.7 BGLAP CRP IL1B IL1RN IL6 TNF
25 synovitis 27.7 CRP IL18 IL1B IL1RN IL6 TNF
26 psoriasis 27.2 IL18 IL1B IL6 LTA S100A9 TNF
27 autoimmune disease 27.1 HLA-DQA1 HLA-DRB1 IL1B IL1RN IL2RA IL6
28 systemic lupus erythematosus 26.7 CRP HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL2RA
29 diabetes mellitus 26.4 CRP HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1B IL1RN
30 rheumatoid arthritis 25.2 CRP HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B
31 asthma 25.1 BGLAP HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B
32 inflammatory bowel disease 22.7 BGLAP CRP HLA-DQA1 HLA-DRB1 IL18 IL1B
33 polyarticular onset juvenile idiopathic arthritis 11.7
34 multicentric carpotarsal osteolysis syndrome 11.3
35 arthropathy, progressive pseudorheumatoid, of childhood 11.3
36 ring chromosome 18 11.1
37 scorpion envenomation 11.0 IL6 TNF
38 cold agglutinin disease 10.9 CRP IL6
39 leukomalacia 10.9 IL6 TNF
40 angioimmunoblastic lymphadenopathy with dysproteinemia 10.9 IL6 TNF
41 microscopic polyangiitis 10.9 HLA-DRB1 TNF
42 anca-associated vasculitis 10.8 HLA-DRB1 IL6 TNF
43 microscopic colitis 10.8 HLA-DRB1 IL6 TNF
44 hemorrhagic fever 10.8 HLA-DRB1 IL6 TNF
45 louse-borne relapsing fever 10.8 CRP IL6 TNF
46 ischemic heart disease 10.8 CRP IL6 TNF
47 streptococcal toxic-shock syndrome 10.8 IL6 LTA TNF
48 critical limb ischemia 10.8 IL6 TNF
49 null-cell leukemia 10.8 IL6 LTA TNF
50 systolic heart failure 10.8 CRP IL6 TNF

Graphical network of the top 20 diseases related to Juvenile Rheumatoid Arthritis:



Diseases related to Juvenile Rheumatoid Arthritis

Symptoms & Phenotypes for Juvenile Rheumatoid Arthritis

Human phenotypes related to Juvenile Rheumatoid Arthritis:

32 (show all 22)
# Description HPO Frequency HPO Source Accession
1 uveitis 32 frequent (33%) HP:0000554
2 skin rash 32 frequent (33%) HP:0000988
3 abnormality of the fingernails 32 frequent (33%) HP:0001231
4 arthritis 32 hallmark (90%) HP:0001369
5 joint dislocation 32 frequent (33%) HP:0001373
6 joint swelling 32 frequent (33%) HP:0001386
7 joint stiffness 32 frequent (33%) HP:0001387
8 pericardial effusion 32 occasional (7.5%) HP:0001698
9 splenomegaly 32 occasional (7.5%) HP:0001744
10 nail pits 32 frequent (33%) HP:0001803
11 fever 32 hallmark (90%) HP:0001945
12 malabsorption 32 frequent (33%) HP:0002024
13 abdominal pain 32 frequent (33%) HP:0002027
14 abnormality of the pleura 32 frequent (33%) HP:0002103
15 hepatomegaly 32 occasional (7.5%) HP:0002240
16 arthralgia 32 hallmark (90%) HP:0002829
17 autoimmunity 32 hallmark (90%) HP:0002960
18 psoriasiform dermatitis 32 frequent (33%) HP:0003765
19 generalized hyperkeratosis 32 frequent (33%) HP:0005595
20 mediastinal lymphadenopathy 32 frequent (33%) HP:0100721
21 cartilage destruction 32 frequent (33%) HP:0100773
22 abnormality of the sacroiliac joint 32 frequent (33%) HP:0100781

UMLS symptoms related to Juvenile Rheumatoid Arthritis:


back pain, muscle cramp, sciatica

GenomeRNAi Phenotypes related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 9.02 BGLAP HAPLN1 HLA-DPB1 IL1RN SLC11A1

MGI Mouse Phenotypes related to Juvenile Rheumatoid Arthritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 IL2RA HAPLN1 IL6 HLA-DQA1 IL18 LTA
2 homeostasis/metabolism MP:0005376 10.03 IL1RN CRP DEK IL2RA IL6 IL18
3 cardiovascular system MP:0005385 10.02 IL1RN CRP IL6 IL18 LTA IL1B
4 immune system MP:0005387 9.97 IL1RN CRP IL2RA IL6 HLA-DQA1 IL18
5 mortality/aging MP:0010768 9.73 IL1RN IL2RA HAPLN1 IL6 IL18 LTA
6 neoplasm MP:0002006 9.17 DEK IL6 IL1B IL1R1 SLC11A1 TNFRSF1B

Drugs & Therapeutics for Juvenile Rheumatoid Arthritis

Drugs for Juvenile Rheumatoid Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 170277-31-3
2
Methotrexate Approved Phase 4,Phase 3,Early Phase 1 1959-05-2, 59-05-2 126941
3
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 185243-69-0
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-24-8 5755
5
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 83-43-2 6741
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 53-03-2 5865
8
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 1 22204-53-1 1302 156391
9
Famotidine Approved Phase 4 76824-35-6 3325
10
Celecoxib Approved, Investigational Phase 4,Phase 3 169590-42-5 2662
11
Esomeprazole Approved, Investigational Phase 4,Phase 1 161796-78-7, 119141-88-7 4594 9579578
12
Sulfasalazine Approved Phase 4,Phase 3 599-79-1 5353980 5359476
13
Ibuprofen Approved Phase 4 15687-27-1 3672
14
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
15
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
16
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
17
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Early Phase 1 58-05-9 143 6006
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Early Phase 1 59-30-3 6037
19 Prednisolone acetate Phase 4,Phase 3,Not Applicable
20 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Methylprednisolone acetate Phase 4,Phase 3,Not Applicable
23 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Not Applicable
24 Folic Acid Antagonists Phase 4,Phase 3,Early Phase 1
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Neuroprotective Agents Phase 4,Not Applicable
27 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
30 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Early Phase 1
31 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Vaccines Phase 4,Phase 3,Not Applicable
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
34 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Vitamin B Complex Phase 4,Phase 3,Early Phase 1
36 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Prednisolone hemisuccinate Phase 4,Phase 3,Not Applicable
40 Prednisolone phosphate Phase 4,Phase 3,Not Applicable
41 Anti-Infective Agents Phase 4,Phase 3,Not Applicable
42 Antiemetics Phase 4,Not Applicable
43 Protective Agents Phase 4,Not Applicable
44 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Antimetabolites Phase 4,Phase 3,Not Applicable,Early Phase 1
48 Autonomic Agents Phase 4,Not Applicable
49 Antimetabolites, Antineoplastic Phase 4,Phase 3,Early Phase 1
50 Antineoplastic Agents, Hormonal Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 214)
# Name Status NCT ID Phase Drugs
1 Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
2 Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4 etanercept;etanercept
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer Unknown status NCT01845922 Phase 4
5 Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis Completed NCT00443430 Phase 4 methotrexate;methotrexate - etanercept - prednisolone arm
6 Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis Completed NCT01563185 Phase 4 800 mg ibuprofen/26.6 mg famotidine
7 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy Completed NCT02196480 Phase 4
8 A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA) Completed NCT01544114 Phase 4 VIMOVO 250/20;VIMOVO 375/20;VIMOVO 500/20
9 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
10 A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects Completed NCT00807846 Phase 4 Celecoxib;Naproxen
11 Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA Completed NCT00792233 Phase 4
12 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
13 Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis Completed NCT00589628 Phase 4 infliximab;infliximab
14 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
15 A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab) Recruiting NCT01734382 Phase 4 Tocilizumab
16 A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA) Recruiting NCT03301883 Phase 4 Tocilizumab;NSAIDs;CSs;MTX
17 Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population Recruiting NCT03069638 Phase 4 Dexmedetomidine;Sedatives/Hypnotics,Other
18 Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis Active, not recruiting NCT00573651 Phase 4
19 Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis Terminated NCT00637780 Phase 4 Sulfasalazine
20 The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Unknown status NCT00012506 Phase 3 TNFR:Fc
21 Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis Completed NCT00690573 Phase 3
22 BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis Completed NCT00095173 Phase 3 Abatacept;Placebo;Abatacept
23 A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis Completed NCT00036374 Phase 3 Infliximab
24 Supplementation With Vitamin D, Calcium or Both on Calcium Absorption and Bone Mineral Content in Children With JRA Completed NCT00570934 Phase 3 Placebo
25 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3 Tocilizumab;Placebo
26 Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA) Completed NCT00034853 Phase 3 meloxicam oral suspension;naproxen oral suspension
27 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA) Completed NCT00642460 Phase 3 tocilizumab [RoActemra/Actemra];Placebo;Non-steroidal anti-inflammatory drugs (NSAIDs);methotrexate;corticosteroids
28 Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use Completed NCT00775437 Phase 3 Adalimumab
29 An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study Completed NCT01727986 Phase 3 tocilizumab [RoActemra/Actemra]
30 Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis Completed NCT01541917 Phase 3
31 A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study Completed NCT01673919 Phase 3 tocilizumab [RoActemra/Actemra]
32 Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis Completed NCT01015547 Phase 3 Infliximab plus methotrexate;Combination of DMARDs;Methotrexate alone
33 A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study Completed NCT01667471 Phase 3 tocilizumab [RoActemra/Actemra]
34 An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Wi Completed NCT00891046 Phase 3 Canakinumab
35 Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA) Completed NCT00048542 Phase 3 OLE BSA Adalimumab +/- MTX;OLE FD Adalimumab +/- MTX
36 Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS Completed NCT00339157 Phase 2, Phase 3 Anakinra
37 A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA) Completed NCT00279747 Phase 3 meloxicam 0.25 mg/kg;meloxicam 0.125 mg/kg;naproxen 10 mg/kg
38 Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis Completed NCT00420251 Phase 3 Genotropin
39 Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis Completed NCT01385826 Phase 2, Phase 3 Anti-tumor necrosis factor alpha monoclonal antibody;placebo
40 Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) Completed NCT00889863 Phase 3 canakinumab;placebo
41 Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis Completed NCT00962741 Phase 3 Etanercept
42 A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA Completed NCT00652925 Phase 3 Celecoxib;Celecoxib;Naproxen
43 Comparison of Two Different Methods of Delivering Local Analgesia During Intra-articular Corticosteroid Injections in Children With Juvenile Idiopathic Arthritis Completed NCT00465504 Phase 3
44 ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab Completed NCT02296424 Phase 3 ACZ885 150 mg (Canakinumab)
45 Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) Completed NCT00144599 Phase 3 MRA(Tocilizumab);placebo
46 Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) Completed NCT00144664 Phase 3 MRA(Tocilizumab)
47 Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) Completed NCT00144612 Phase 3 MRA(Tocilizumab)
48 Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) Completed NCT00144625 Phase 3 MRA(Tocilizumab)
49 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3 Alendronate
50 Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3 Intravenous immunoglobulin

Search NIH Clinical Center for Juvenile Rheumatoid Arthritis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: arthritis, juvenile

Genetic Tests for Juvenile Rheumatoid Arthritis

Anatomical Context for Juvenile Rheumatoid Arthritis

The Foundational Model of Anatomy Ontology organs/tissues related to Juvenile Rheumatoid Arthritis:

19
Joint

MalaCards organs/tissues related to Juvenile Rheumatoid Arthritis:

41
Testes, Bone, Eye, Skin, T Cells, Liver, Brain

Publications for Juvenile Rheumatoid Arthritis

Articles related to Juvenile Rheumatoid Arthritis:

(show top 50) (show all 677)
# Title Authors Year
1
Simultaneous Quadruple Joint Replacement (QJR) in Disabling Juvenile Rheumatoid Arthritis - a Case Report with Review of Literature. ( 29911143 )
2018
2
Levels of Health Theory With the Example of a Case of Juvenile Rheumatoid Arthritis. ( 29896977 )
2018
3
50 Years Ago in The Journal of Pediatrics: Rash Associated with Juvenile Rheumatoid Arthritis. ( 29703372 )
2018
4
Concurrent one-stage total knee and hip arthroplasty due to sequel of juvenile rheumatoid arthritis: A case report. ( 29145334 )
2017
5
Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature. ( 28223750 )
2017
6
Macrophage activation syndrome as a complication of juvenile rheumatoid arthritis. ( 29077164 )
2017
7
A study on the physical fitness of children with juvenile rheumatoid arthritis. ( 28356614 )
2017
8
50 Years Ago in The Journal of Pediatrics: Monarticular Juvenile Rheumatoid Arthritis. ( 28746043 )
2017
9
Lack of Association between STAT4 Single Nucleotide Polymorphisms and Iranian Juvenile Rheumatoid Arthritis Patients. ( 28524764 )
2017
10
Successful Treatment of Focal Segmental Glomerulosclerosis after Kidney Transplantation with Plasma Exchange and Abatacept in a Patient with Juvenile Rheumatoid Arthritis. ( 27088031 )
2016
11
Effect of Electromyographic Biofeedback Training on Pain, Quadriceps Muscle Strength, and Functional Ability in Juvenile Rheumatoid Arthritis. ( 27149595 )
2016
12
Maternal juvenile rheumatoid arthritis may be associated with preterm birth but not poor fetal growth. ( 26675002 )
2016
13
Relation between functional ability and health-related quality of life of children with juvenile rheumatoid arthritis. ( 25931742 )
2015
14
Treatment in juvenile rheumatoid arthritis and new treatment options. ( 26078691 )
2015
15
Shortening femoral osteotomy with stemmed resurfacing total knee arthroplasty for severe flexion contracture in Juvenile Rheumatoid Arthritis. ( 25972704 )
2015
16
Association of neopterin as a marker of immune system activation and juvenile rheumatoid arthritis activity. ( 25727025 )
2015
17
Kre-Celazine(Ar) as a viable treatment for juvenile rheumatoid arthritis/juvenile idiopathic arthritis - a pilot study. ( 24896807 )
2014
18
The outcome of total elbow arthroplasty in juvenile idiopathic arthritis (juvenile rheumatoid arthritis) patients. ( 24906903 )
2014
19
The surgical management of atlanto-axial subluxation in juvenile rheumatoid arthritis. ( 25427669 )
2014
20
Repair of radiographic hip joint in juvenile rheumatoid arthritis patients treated with etanercept plus methotrexate. ( 24746812 )
2014
21
Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. ( 25228459 )
2014
22
50 years ago in the Journal of Pediatrics: clinical and serologic observations in patients with juvenile rheumatoid arthritis and their relatives. ( 23438918 )
2013
23
Juvenile rheumatoid arthritis and asthma, but not childhood-onset systemic lupus erythematosus are associated with FCRL3 polymorphisms in Mexicans. ( 23070121 )
2013
24
Juvenile rheumatoid arthritis. ( 23763801 )
2013
25
Sexual maturation in Egyptian boys and girls with juvenile rheumatoid arthritis. ( 23430157 )
2013
26
The Importance of General Self-Efficacy for the Quality of Life of Adolescents with Diabetes or Juvenile Rheumatoid Arthritis Over Time: A Longitudinal Study among Adolescents and Parents. ( 24400286 )
2013
27
Hepatitis B virus reactivation in a juvenile rheumatoid arthritis patient under treatment and its successful management: a complicated case. ( 22147111 )
2013
28
Monoarticular septic arthritis in a patient with juvenile rheumatoid arthritis under etanercept treatment. ( 20349235 )
2012
29
Recurrent fever of unknown origin (FUO): aseptic meningitis, hepatosplenomegaly, pericarditis and a double quotidian fever due to juvenile rheumatoid arthritis (JRA). ( 21453973 )
2012
30
Dominant vertebral artery injury during posterior atlantoaxial transarticular screw fixation in a juvenile rheumatoid arthritis patient with atlantoaxial subluxation. ( 22358143 )
2012
31
Dental surgery and anesthetic precautions of a patient with Down syndrome and juvenile rheumatoid arthritis: a case report. ( 23265174 )
2012
32
Relation of dry eye to disease activity in juvenile rheumatoid arthritis. ( 21928273 )
2012
33
Lymphomatoid papulosis in a patient treated with adalimumab for juvenile rheumatoid arthritis. ( 23257839 )
2012
34
MiR-146a polymorphism is associated with asthma but not with systemic lupus erythematosus and juvenile rheumatoid arthritis in Mexican patients. ( 22823586 )
2012
35
T-cell lymphoma masquerading as juvenile rheumatoid arthritis. ( 22486797 )
2012
36
Dosing celecoxib in pediatric patients with juvenile rheumatoid arthritis. ( 21878579 )
2012
37
The referral pattern and evaluation of children prior to the diagnosis of pauciarticular juvenile rheumatoid arthritis. ( 21525080 )
2012
38
HMOX1 promoter (GT)n polymorphim is associated with childhood-onset systemic lupus erythematosus but not with juvenile rheumatoid arthritis in a Mexican population. ( 22338608 )
2012
39
Sexual maturation in boys with juvenile rheumatoid arthritis. ( 20429008 )
2011
40
Infliximab for progressive peripheral ulcerative keratitis in a patient with juvenile rheumatoid arthritis. ( 21331698 )
2011
41
MRI evaluation of the temporomandibular joints in juvenile rheumatoid arthritis: a retrospective review. ( 24059900 )
2011
42
Study of serological and clinical factors among juvenile rheumatoid arthritis cases admitted to Mofid Children's Hospital and Imam Hossein Hospital, Tehran, Iran. ( 21970211 )
2011
43
Is this acute lymphoblastic leukaemia or juvenile rheumatoid arthritis. ( 22315865 )
2011
44
Hypersensitive joint reaction after etanercept treatment in a patient with juvenile rheumatoid arthritis. ( 21362794 )
2011
45
Prevalence of IgA deficiency in children with juvenile rheumatoid arthritis. ( 21358013 )
2011
46
Acute lymphoblastic leukemia masquerading as juvenile rheumatoid arthritis: response. ( 20443115 )
2011
47
Measures of health status and quality of life in juvenile rheumatoid arthritis: Pediatric Quality of Life Inventory (PedsQL) Rheumatology Module 3.0, Juvenile Arthritis Quality of Life Questionnaire (JAQQ), Paediatric Rheumatology Quality of Life Scale (PRQL), and Childhood Arthritis Health Profile (CAHP). ( 22588764 )
2011
48
Growth hormone deficiency, short stature, and juvenile rheumatoid arthritis in a patient with autoimmune polyglandular syndrome type 1: case report and brief review of the literature. ( 22363878 )
2011
49
Longitudinal growth attainments of Indian boys with juvenile rheumatoid arthritis. ( 20054693 )
2011
50
Clinical, laboratory, and ultrasound assessment of the knee in juvenile rheumatoid arthritis. ( 21573036 )
2011

Variations for Juvenile Rheumatoid Arthritis

ClinVar genetic disease variations for Juvenile Rheumatoid Arthritis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XY;t(8;9)(q13;p22)dn Translocation Pathogenic

Expression for Juvenile Rheumatoid Arthritis

Search GEO for disease gene expression data for Juvenile Rheumatoid Arthritis.

Pathways for Juvenile Rheumatoid Arthritis

Pathways related to Juvenile Rheumatoid Arthritis according to KEGG:

37
# Name Kegg Source Accession
1 Cytokine-cytokine receptor interaction hsa04060
2 Jak-STAT signaling pathway hsa04630

Pathways related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 CRP HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B
2
Show member pathways
13.7 IL18 IL1B IL1R1 IL1RN IL2RA IL6
3
Show member pathways
13.53 IL18 IL1B IL1R1 IL2RA IL6 LTA
4
Show member pathways
13.43 IL18 IL1B IL1R1 IL2RA IL6 LTA
5
Show member pathways
13.32 IL18 IL1B IL1R1 IL2RA IL6 LTA
6
Show member pathways
13.29 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B IL1R1
7
Show member pathways
12.9 IL2RA IL6 LTA TNF TNFRSF1B
8
Show member pathways
12.77 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B IL2RA
9
Show member pathways
12.76 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B IL2RA
10
Show member pathways
12.74 IL1B IL1R1 IL6 LTA TNF TNFRSF1B
11
Show member pathways
12.69 IL1B IL1R1 LTA TNF TNFRSF1B
12
Show member pathways
12.68 IL18 IL1B IL2RA IL6 LTA TNF
13 12.6 IL1B IL1RN IL2RA TNF TNFRSF1B
14
Show member pathways
12.56 IL1B IL1R1 LTA TNF TNFRSF1B
15 12.38 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1R1 IL2RA IL6
16
Show member pathways
12.35 CRP IL1B IL6 TNF
17
Show member pathways
12.35 IL1B IL6 S100A9 TNF
18
Show member pathways
12.3 IL1B IL1R1 IL6 TNF
19
Show member pathways
12.3 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1B TNF
20
Show member pathways
12.29 IL18 IL1B IL1R1 IL6 LTA TNF
21 12.27 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B IL6
22
Show member pathways
12.23 IL18 IL1B IL1R1 IL1RN IL6 TNF
23
Show member pathways
12.23 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B IL1R1
24
Show member pathways
12.22 IL1B IL1R1 IL6 TNF
25 12.21 IL1B IL1RN IL6 TNF
26
Show member pathways
12.21 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL2RA
27
Show member pathways
12.13 IL18 IL1B IL1R1 IL2RA IL6 TNFRSF1B
28 12.05 IL1B IL1R1 IL6 TNF
29 12.05 IL18 IL1B IL6 TNF TNFRSF1B
30
Show member pathways
12.03 HLA-DRB1 IL18 IL1B IL1R1 IL2RA
31 12.01 IL1B IL6 LTA TNF TNFRSF1B
32 11.95 IL1B IL1R1 IL6 TNF
33 11.94 IL1B IL1R1 LTA TNF
34 11.92 HLA-DPB1 HLA-DQA1 HLA-DRB1
35 11.9 IL1B IL6 TNF
36 11.84 IL18 IL1B IL6
37 11.84 IL18 IL1B IL1R1 IL2RA LTA TNF
38 11.78 IL1B IL6 TNF
39 11.77 IL1B IL6 TNF
40 11.76 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B IL6
41 11.69 IL1B IL6 TNF
42
Show member pathways
11.69 IL1B IL6 TNF
43 11.66 IL18 IL1B IL6 TNF
44 11.65 IL1R1 LTA TNF TNFRSF1B
45 11.63 HLA-DPB1 HLA-DQA1 HLA-DRB1
46 11.6 IL18 IL1B IL6 TNF
47
Show member pathways
11.58 LTA TNF TNFRSF1B
48 11.56 IL18 IL1B TNF
49 11.55 BGLAP IL1B IL6 TNF
50
Show member pathways
11.5 IL1B IL1R1 TNF

GO Terms for Juvenile Rheumatoid Arthritis

Cellular components related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.92 HLA-DPB1 HLA-DRB1 IL1R1 IL2RA TNF
2 extracellular space GO:0005615 9.91 BGLAP CRP IL18 IL1B IL1RN IL6
3 external side of plasma membrane GO:0009897 9.81 HLA-DRB1 IL1R1 IL2RA TNF
4 endosome membrane GO:0010008 9.78 HLA-DPB1 HLA-DQA1 HLA-DRB1 SLC11A1
5 lysosome GO:0005764 9.77 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1B SLC11A1
6 trans-Golgi network membrane GO:0032588 9.67 HLA-DPB1 HLA-DQA1 HLA-DRB1
7 endocytic vesicle membrane GO:0030666 9.63 HLA-DPB1 HLA-DQA1 HLA-DRB1
8 ER to Golgi transport vesicle membrane GO:0012507 9.61 HLA-DPB1 HLA-DQA1 HLA-DRB1
9 transport vesicle membrane GO:0030658 9.58 HLA-DPB1 HLA-DQA1 HLA-DRB1
10 clathrin-coated endocytic vesicle membrane GO:0030669 9.5 HLA-DPB1 HLA-DQA1 HLA-DRB1
11 extracellular region GO:0005576 9.4 BGLAP CRP HAPLN1 IL18 IL1B IL1R1
12 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.33 HLA-DPB1 HLA-DQA1 HLA-DRB1
13 MHC class II protein complex GO:0042613 9.13 HLA-DPB1 HLA-DQA1 HLA-DRB1

Biological processes related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.99 IL18 IL1B IL1RN IL6 LTA TNF
2 MAPK cascade GO:0000165 9.98 IL18 IL1B IL2RA TNF
3 positive regulation of gene expression GO:0010628 9.97 CRP IL18 IL1B IL6 SLC11A1 TNF
4 response to lipopolysaccharide GO:0032496 9.94 IL1B LTA SLC11A1 TNFRSF1B
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 IL1B IL6 S100A9 TNF
6 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.87 HLA-DPB1 HLA-DQA1 HLA-DRB1
7 interleukin-1-mediated signaling pathway GO:0070498 9.86 IL1B IL1R1 IL1RN
8 cytokine-mediated signaling pathway GO:0019221 9.86 IL18 IL1B IL1R1 IL1RN IL2RA IL6
9 regulation of inflammatory response GO:0050727 9.85 IL1R1 S100A9 TNF
10 T cell costimulation GO:0031295 9.84 HLA-DPB1 HLA-DQA1 HLA-DRB1
11 cellular response to organic cyclic compound GO:0071407 9.84 IL18 IL1B TNF
12 interferon-gamma-mediated signaling pathway GO:0060333 9.83 HLA-DPB1 HLA-DQA1 HLA-DRB1
13 defense response to Gram-positive bacterium GO:0050830 9.83 CRP IL6 LTA TNF
14 humoral immune response GO:0006959 9.81 IL6 LTA TNF
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.81 IL18 IL6 TNF
16 positive regulation of interleukin-6 production GO:0032755 9.8 IL1B IL6 TNF
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.78 IL18 IL1B TNF
18 antigen processing and presentation GO:0019882 9.77 HLA-DPB1 HLA-DQA1 HLA-DRB1
19 response to glucocorticoid GO:0051384 9.76 BGLAP IL1RN IL6 TNF
20 positive regulation of phagocytosis GO:0050766 9.74 IL1B SLC11A1 TNF
21 lipopolysaccharide-mediated signaling pathway GO:0031663 9.72 IL18 IL1B TNF
22 regulation of osteoclast differentiation GO:0045670 9.7 BGLAP TNF
23 negative regulation of growth of symbiont in host GO:0044130 9.69 LTA TNF
24 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.68 IL1B TNF
25 T-helper 1 type immune response GO:0042088 9.67 HLA-DRB1 IL18
26 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.67 IL18 IL1B
27 positive regulation of T cell proliferation GO:0042102 9.67 HLA-DPB1 IL1B IL2RA IL6
28 positive regulation of chemokine biosynthetic process GO:0045080 9.65 IL1B TNF
29 interleukin-6 production GO:0032635 9.65 IL18 IL1B
30 regulation of establishment of endothelial barrier GO:1903140 9.65 IL1B TNF
31 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 IL1B TNF TNFRSF1B
32 inflammatory response GO:0006954 9.65 CRP IL18 IL1B IL1RN IL2RA IL6
33 positive regulation of interferon-gamma production GO:0032729 9.63 HLA-DPB1 IL18 IL1B LTA SLC11A1 TNF
34 positive regulation of fever generation GO:0031622 9.62 IL1B TNF
35 fever generation GO:0001660 9.62 IL1B IL1RN
36 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.61 IL1RN IL6
37 inflammatory response to antigenic stimulus GO:0002437 9.61 HLA-DRB1 IL1B IL2RA
38 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.59 LTA TNF
39 sequestering of triglyceride GO:0030730 9.58 IL1B TNF
40 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.58 HLA-DPB1 HLA-DQA1 HLA-DRB1
41 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.56 IL1B TNF
42 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.54 LTA TNF
43 negative regulation of lipid storage GO:0010888 9.5 CRP IL6 TNF
44 immune response GO:0006955 9.44 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B IL1R1
45 immune system process GO:0002376 10.08 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL2RA S100A9

Molecular functions related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.16 HLA-DQA1 HLA-DRB1
2 peptide antigen binding GO:0042605 9.13 HLA-DPB1 HLA-DQA1 HLA-DRB1
3 cytokine activity GO:0005125 9.1 IL18 IL1B IL1RN IL6 LTA TNF

Sources for Juvenile Rheumatoid Arthritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....